Tetraspanin (TSP-17) Protects Dopaminergic Neurons against 6-OHDA-Induced Neurodegeneration in

Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons. While hereditary forms are known, most cases are attributable to a combination of genetic and environmental risk factors. In PD models, dopaminergic neurodegeneration can be triggered by neurotoxins such as 6-hydroxydopamine (6-OHDA). This drug, which is taken up by the presynaptic dopamine reuptake transporter (DAT-1), also causes the selective death of C. elegans dopaminergic neurons. We found that TSP-17, a member of the tetraspanin family of membrane proteins, protects dopaminergic neurons from 6-OHDA-induced degeneration. We provide evidence that TSP-17 inhibits the C. elegans dopamine transporter DAT-1, leading to increased neuronal 6-OHDA uptake in tsp-17 mutants. TSP-17 also protects against toxicity conferred by excessive intracellular dopamine. TSP-17 interacts with the DOP-2 dopamine receptor, possibly as part of a pathway that negatively regulates DAT-1. tsp-17 mutants have subtle behavioral phenotypes that are partly conferred by aberrant dopamine signaling. In summary, we have used C. elegans genetics to model key aspects of PD.

Published in the journal: . PLoS Genet 10(12): e32767. doi:10.1371/journal.pgen.1004767
Category: Research Article
doi: 10.1371/journal.pgen.1004767


Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons. While hereditary forms are known, most cases are attributable to a combination of genetic and environmental risk factors. In PD models, dopaminergic neurodegeneration can be triggered by neurotoxins such as 6-hydroxydopamine (6-OHDA). This drug, which is taken up by the presynaptic dopamine reuptake transporter (DAT-1), also causes the selective death of C. elegans dopaminergic neurons. We found that TSP-17, a member of the tetraspanin family of membrane proteins, protects dopaminergic neurons from 6-OHDA-induced degeneration. We provide evidence that TSP-17 inhibits the C. elegans dopamine transporter DAT-1, leading to increased neuronal 6-OHDA uptake in tsp-17 mutants. TSP-17 also protects against toxicity conferred by excessive intracellular dopamine. TSP-17 interacts with the DOP-2 dopamine receptor, possibly as part of a pathway that negatively regulates DAT-1. tsp-17 mutants have subtle behavioral phenotypes that are partly conferred by aberrant dopamine signaling. In summary, we have used C. elegans genetics to model key aspects of PD.


Parkinson's Disease (PD) is the second most common neurodegenerative disease, after Alzheimer's disease, and affects ∼2% of the population aged over 65 years. Loss of dopaminergic neurons is a pathological hallmark of PD [1], [2] and aspects of this neurodegeneration have been modeled in C. elegans [3], [4]. The etiology of PD is largely unknown and its heritability is generally rather low; however ∼5–10% of cases are associated with monogenetically inherited mutations [5]. Approximately 15 disease loci are known, most of which are conserved in C. elegans [6], [7]. The vast majority of PD cases are ‘sporadic’ with no clear family history. Besides aging, epidemiological studies have shown risk factors for ‘sporadic’ PD to include a long-term history of rural living, farming, well-water drinking and pesticide exposure. The most extreme examples of toxin-induced PD-like symptoms were linked to the accidental exposure to MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Similar to sporadic PD cases, PD-like symptoms resulting from MPTP exposure could be alleviated by administration of the dopamine precursor L-3,4-dihydrooxyphenylalanine (L-DOPA) [8]. Exposure to pesticides such as paraquat and rotenone has also been implicated in PD development [9]. The disease is therefore thought to be triggered by a combination of environmental factors and genetic susceptibility [5].

MPTP, paraquat and rotenone all block the mitochondrial electron transport chain, leading to oxidative damage [10], and have been extensively used to model PD neurodegeneration. 6-Hydroxydopamine (6-OHDA), an oxidation product of dopamine, is another neurotoxin widely used in mammalian PD models to induce the specific degeneration of dopaminergic neurons [11]. 6-OHDA was initially identified as a metabolite of dopamine [12], and there is some evidence that 6-OHDA exposure might be linked to PD. 6-OHDA was also identified as a naturally occurring amine in human urine, and has been detected at higher concentrations in PD patients [13]. Furthermore, high 6-OHDA levels were found in postmortem brain samples from PD patients [14]. It has been reported that 6-OHDA interaction with oxygen results in the production of reactive oxygen species (ROS), which in turn trigger free radical-mediated neuronal degeneration [2], [12]. Other dopamine metabolites may also cause oxidative damage [15]. Nevertheless, the mechanism by which 6-OHDA induces neuronal degeneration remains largely unknown [16].

Although there is no treatment to prevent or halt neuronal loss, L-DOPA administration is still one of the most effective treatments for alleviating PD symptoms [17], [18]. However, the effectiveness of L-DOPA declines over time. Prolonged L-DOPA treatment is also potentially neurotoxic [11], [15]. Although not confirmed in a large longitudinal study of L-DOPA use in PD patients (ELLDOPA trial), this nevertheless remains a major concern [19].

C. elegans has been used as a model to study the structure and function of the nervous system, which in hermaphrodite worms consists of 302 neurons [20], [21]. C. elegans dopaminergic neurons are functionally related to those of humans. The genes driving the biochemical processes involved in dopamine metabolism (as well as most PD-associated loci) [6] are also highly conserved in worms [22]. Dopaminergic neurons can be readily visualized in vivo using appropriate GFP markers. Analogous to vertebrate systems, dopaminergic neurons undergo neurodegeneration upon treatment with 6-OHDA. It has been shown that 6-OHDA can enter dopaminergic neurons through the DAT-1 dopamine transporter and thus trigger their degeneration [3]. The exact type of cellular death that occurs following 6-OHDA intoxication is unknown. Electron microscopy has shown apoptotic-like condensed chromatin structures in dying neurons, suggesting that 6-OHDA induces apoptosis. However, 6-OHDA-induced neurodegeneration in C. elegans is independent of CED-4/Apaf1 and CED-3/caspase, two components of the core apoptotic machinery [3]. In an independent study, inactivation of C. elegans autophagy genes partially suppressed 6-OHDA-induced dopaminergic death, suggesting that autophagy might also be involved in this process [23].

During synaptic transmission most of the released dopamine is transported back into the presynaptic terminal by the dopamine reuptake transporter (DAT1) (for a review, see [24]. Therefore, activity of this transporter affects the duration and extent of dopamine signaling. Mammalian cell experiments led to the identification of several proteins that interact with DAT1 to modulate its activity, cell surface expression and trafficking. These include protein kinase C, dopamine D2 receptors (discussed below), SNCA and parkin [25][28]. The physiological actions of dopamine are mediated by conserved seven-transmembrane dopamine receptors, designated D1–5. Dopamine receptors are coupled to guanosine triphosphate-binding proteins (G proteins) and are classified into D1 or D2 type dopamine receptors based on their antagonistic effect on adenylyl cyclase activity [29], [30]. D1 dopamine receptors, DOP-1 in worms, are solely found in postsynaptic dopamine-receptive cells, whereas in C. elegans the D2 type receptors DOP-2 and DOP-3 are expressed pre and postsynaptically, respectively [31][33].

In vertebrates, the dopamine system plays a crucial role in regulating movement, reward and cognition. Dopamine-deficient newborn mice die as a result of severe motor impairments [34], [35]. In contrast, C. elegans mutants defective in dopamine synthesis are viable, thus facilitating investigations into dopamine-mediated behavior in these animals. Dopaminergic neurons in C. elegans are required for specific, well-described and quantifiable behaviors, often associated with locomotion and feeding. For instance, the basal slowing response allows worms to reduce their speed when encountering a bacterial lawn, which is their food source [36]. Another behavior mediated by dopamine signaling is referred to as “swimming-induced paralysis” (SWIP): dat-1-deficient worms exhibit rapid paralysis in liquid, unlike wild-type controls [37].

Using an unbiased forward genetic approach we identified tsp-17 as a gene that protects dopaminergic neurons from 6–OHDA-mediated neurodegeneration. We provide evidence that TSP-17 regulates DAT-1 transporter activity. Furthermore, our results suggest that DAT-1 regulation by TSP-17 is partly mediated by D2 dopamine receptors.


In order to find genes that protect dopaminergic neurons, we performed a genetic screen for mutants conferring hypersensitivity to 6-OHDA. By adapting procedures initially established by Nass et al. [3] and using the same pdat-1::GFP reporter that highlights dopaminergic neurons, we screened ∼2500 F2 ethyl methanesulfonate (EMS)-mutagenized worms at the L1 developmental stage by incubating with 10 mM 6-OHDA for 1 h. This procedure, which is based on reduced, altered, or absent pdat-1::GFP expression, does not lead to neurodegeneration in >95% of wild-type worms, thus allowing the identification of mutants conferring hypersensitivity to 6-OHDA. Of the initial five mutant candidates, only gt1681 maintained a strong hypersensitive phenotype upon backcrossing (Figure 1A, Figure S1). 6-OHDA-induced degeneration of both wild-type and gt1681 neurons exhibits the same morphological features and pattern of degeneration initially described by Nass et al. [3]. Axonal blebbing becomes apparent (Figure 1B, inset, arrows) a feature also consistent with morphological changes previously observed by electron microscopy. Worms were scored 24, 48 and 72 h after intoxication. Neurons were lost in less than 10% of wild-type worms after 72 h. In contrast, all dopaminergic neurons were lost in ∼40% of gt1681 worms and partial dopaminergic loss was observed in an additional ∼30% of mutant worms after only 24 h (Figure 1A). The extent of neurodegeneration was further increased 72 h after intoxication, with ∼90% of worms displaying total dopaminergic loss at the adult stage (Figure 1A). Enhanced neurodegeneration in the gt1681 background, albeit to a lesser extent, also occurred in L2, L3 and L4 larvae treated with 6-OHDA; no such enhancement was seen in adults (Figure 1C). To exclude the possibility that neurodegeneration might be caused by increased net 6-OHDA uptake at the organismal level, we took advantage of the partial growth retardation conferred by 6-OHDA treatment. By scoring for progression to ensuing developmental stages, we found the growth of wild-type and gt1681 worms to be similarly retarded upon toxin treatment, suggesting that gt1681 specifically affects dopaminergic neurons (Figure 1D).

<i>gt1681</i> mutants are hypersensitive to 6-OHDA.
Fig. 1. gt1681 mutants are hypersensitive to 6-OHDA.
A. The extent of dopaminergic degeneration is indicated for wild-type and gt1681 mutant worms after intoxication with 10 mM 6-OHDA. Neurodegeneration of L1 worms was scored after 24, 48 and 72 h as described in Materials and Methods, and categorized as “complete loss,” “partial loss” or “no loss” phenotypes (labeled black, white and gray, respectively). Asterisks represent statistical significance of differences from wild-type (****p<0.00001). B. Representative images showing progressive stages of dopaminergic neurodegeneration. Absence of degeneration in wild-type (upper left panel) and complete degeneration in gt1681 mutant worms 72 h post 6-OHDA intoxication (upper right panel, complete degeneration); lower panel and inset are examples of partial degeneration in gt1881. Arrows indicate ‘blebs in degenerating neurons. C. Extent of neurodegeneration at various developmental stages in wild-type and gt1681 mutant worms 72 h post 6-OHDA intoxication. D. In wild-type and gt1681 worms, development is equally retarded following treatment with 6-OHDA. Progression to various developmental stages was scored once 95% of untreated worms reached adulthood.

The gt1681 mutant is recessive in hermaphrodites (Figure 2A). Genetic linkage was established by single nucleotide polymorphism (SNP) mapping, which placed gt1681 on the left arm of the X chromosome. Using unc-20 and lon-2 genetic markers to perform three-factor mapping, the locus was further refined to ∼10 map units. A cross between an unc-20 gt1681 lon-2 triple mutant and the CB4856 “Hawaii” mapping strain enabled us to assess the position of single recombination events relative to gt1681. This analysis localized gt1681 to an interval between nucleotides 3,659,480 and 3,737,466 on the physical map. In parallel, next generation sequencing revealed a single exonic mutation within this interval, leading to a guanine to adenine substitution in the C02F12.1 open reading frame and resulting in a glycine to glutamic acid change at position 109 of the encoded protein (Figure 2B). C02F12.1 encodes a tetraspanin family, integral membrane protein called TSP-17 (see below). Rescue of the phenotype by a fosmid (WRM0626aC02) encompassing tsp-17 and by a tsp-17-encoding transgene (Figure 2C) provides further evidence that gt1681 confers 6-OHDA hypersensitivity. Hypersensitivity is also conferred by the vc2026 allele, a substitution obtained via the Million Mutation Project [38] that results in a glycine to arginine change at position 109 (Figure 2B, 2D). Finally, two deletion alleles, generously provided by the Japanese Knockout Consortium, affecting the first exons of tsp-17 also confer hypersensitivity to 6-OHDA-mediated neurotoxicity (Figure 2B, 2D) as does the trans-heterozygous gt1681/tm4995 mutant combination (Figure 2A).

The TSP-17 tetraspanin family member protects dopaminergic neurons from 6-OHDA.
Fig. 2. The TSP-17 tetraspanin family member protects dopaminergic neurons from 6-OHDA.
A. Extent of neurodegeneration in heterozygous and trans-heterozygous worms 72 h post 6-OHDA intoxication. B. Schematic gene model of the two isoforms of tsp-17. Alleles used in this study are indicated. C. Complementation of tsp-17 expressed under its own promoter (3rd column strain TG2439) and under the dat-1 promoter (4th column, strain TG2440). Data presented is from scoring the extent of neurodegeneration 72 h post 6-OHDA intoxication. Asterisks represent statistical significance of differences between tsp-17 and the rescuing lines (****p<0.0001). D. 6-OHDA hypersensitivity conferred by various tsp-17 alleles. E. Alignment of nematode TSP-17 to the most closely related human tetraspanins. Blue bars indicate transmembrane domains and brown bars designate extracellular loops (EC1 and EC2). The arrow indicates amino acid G109, which is mutated in the C. elegans gt1681 and vc2026 mutants. The red box indicates the CCG motif in the EC2, which is highly conserved throughout the tetraspanin protein family. Hs, Homo sapiens; Ce, Caenorhabditis elegans; Cbn, C. brenneri; Cre, C. remanei; Cbr, C. briggsae.

Tetraspanins constitute a large protein family, with 30 and 21 members encoded in the human and C. elegans genomes, respectively [39][41]. Most tetraspanins have not been functionally characterized. In vertebrates, tetraspanins are suggested to be involved in cell–cell fusion, cell adhesion, cell motility and tumor metastasis [42]. In C. elegans, TSP-12 is involved in modulating Notch signaling, and specific hypodermal TSP-15 expression is required to mediate covalent tyrosine–tyrosine cross-linking during cuticle formation [43], [44]. C. elegans tsp-17 is predicted to encode two isoforms. The large isoform, C02F12.1b, encodes a 312 amino acid protein containing four TM domains. The short isoform, C02F12.1a, encodes a 243 amino acid protein that, unlike typical tetraspanins, contains only three transmembrane domains and does not have an intracellular N-terminus. The amino acid change at position 109 in gt1681 affects a highly conserved residue in the third transmembrane domain of the long isoform (Figure 2B, 2E). We confirmed expression of mRNAs encoding for both isoforms, and verified the predicted intron–exon structure (Figure 2B). Using BLAST protein analysis of C. elegans TSP-17, we found the most likely human orthologs of TSP-17 to be CD63, Tspan5 and CD82 (Figure 2E). A previous phylogenetic analysis placed TSP-17 within the human CD82 subfamily [45]. However, our attempts to firmly establish an orthologous relationship between TSP-17 and a single human tetraspanin or a distinct subfamily of human tetraspanins were unsuccessful. Our phylogenetic analysis included all tetraspanins from several nematodes, arthropods, cnidarians and chordates (Figure S2). We speculate that the rapid evolution of this protein family, as often occurs with membrane proteins, compromised our ability to firmly identify a human ortholog of C. elegans TSP-17.

To assess the TSP-17 expression pattern, we used biolistic bombardment to generate transgenic worms (TG2439) expressing a tsp-17::GFP gene fusion (NM001) under the control of its own promoter and 3′UTR. A dat-1 (promoter)::mCherry fusion (PBI001) was co-bombarded to mark dopaminergic neurons. The tsp-17::GFP gene fusion largely suppressed the hypersensitivity phenotype conferred by tsp-17, thus confirming its functionality (Figure 2C, bar 3). Importantly, fusion protein expression was observed in all dopaminergic neurons: it was uniform along axons and dendrites of both dorsal and ventral pairs of CEP neurons, as well as in ADE neurons (Figure 3A–I, arrows indicate axons and dendrites) and in the posterior PDE neurons. Within the cell body, the TSP-17::GFP fusion seems to be excluded from the nucleus, a pattern that is more evident in a “close-up” image of a PDE neuron, where the signal appears to form a ring-like structure around the nucleus (Figure 3J–L arrowheads). mCherry aggregates (which are not linked to neurodegeneration) form dot-like structures in dendrites and axons (arrows), and the surrounding TSP-17 fluorescent signal suggests plasma membrane expression (arrow, Figure 3K). TSP-17 enrichment at the plasma membrane can be observed most prominently in the large cells of the vulva and the sheath cells enclosing the spermatheca (Figure 3M, N). In the spermatheca, TSP-17::GFP expression is also clearly enriched around the nucleus (Figure 3N, arrowheads), possibly localizing to the nuclear membrane or endoplasmic reticulum (Figure 3N, arrowhead). Analysis of subcellular localization in the vulva and spermatheca revealed that the TSP-17::GFP (gt1681) mutant protein is uniformly expressed in the cytoplasm, with a loss of enrichment at the plasma membrane and around the nucleus (Figure S3A). Thus, the gt1681 mutation, which leads to an amino acid change in the fourth transmembrane domain, might compromise the membrane localization of TSP-17 and therefore block its function. TSP-17::GFP is also expressed in multiple neurons throughout worm development. For instance, the NSM serotonergic neuron, which is characterized by extensive axon sprouting, shows TSP-17::GFP expression along its entire length (Figure 3O). Prominent expression was also observed in the muscles of early stage larvae (Figure 3P). Finally expression also appears to be apparent in muscles of the adult head (Figure 3B, C, H, I). In summary, the TSP-17::GFP expression indicates that TSP-17 is expressed in dopaminergic neurons. Transgene expression in dopaminergic neurons was also confirmed by analyzing a TSP-17::GFP expressing transgenic strain crossed to a DAT-1 reporter strain (Figure S3B). We cannot rule out expression of TSP-17 not uncovered by the transgene, due to missing regulatory sequences. We next wanted to investigate whether TSP-17 expression in dopaminergic neurons protects them from 6-OHDA-mediated neurodegeneration. By direct injection of transgenes into the gonad, we generated transgenic worms overexpressing TSP-17 under the control of the dat-1 promoter. Consistent with TSP-17 expression in dopaminergic neurons, we found partial rescue of the hypersensitivity conferred by gt1681 (Figure 2C, compare bars 1, 2 and 4). Interestingly, overexpression of TSP-17 and TSP-17 (gt1681) under the dat-1 promoter led to spontaneous neurodegeneration (Figure S4A, B, respectively). This phenotype tended to be more severe following TSP-17 (gt1681) overexpression. Taken together, these data indicate that TSP-17 indeed functions in dopaminergic neurons, and that excessive TSP-17, especially the mutant form, leads to spontaneous neurodegeneration.

TSP-17::GFP expression.
Fig. 3. TSP-17::GFP expression.
Analysis of the TG2439 strain containing dopaminergic neurons labeled by mCherry and tsp-17 C-terminally fused to GFP and driven by its own promoter. A, D, G, J. Dopaminergic neurons expressing the mCherry marker. Neurons are indicated. White arrows highlight dendrites and axons. B, E. H, K. Expression of TSP-17::GFP. C, F, I, L. Merged images. White arrows highlight dendrites and axons. K, L, N. The arrow-heads indicate TSP-17::GFP signal enrichment around the nucleus. Expression in the vulva (M), the spermatheca (N), a NSM neuron (O), and in body wall muscle cells (P).

We next wished to address how TSP-17 protects dopaminergic neurons. We hypothesized that TSP-17 might affect dopamine synthesis, or dopamine and 6-OHDA uptake or degradation. Dopamine metabolism is itself a source of oxidative stress and may initiate ROS-mediated injury to dopaminergic neurons. The link between excessive dopamine exposure and toxicity is controversial, but overexpression of CAT-2, the rate-limiting enzyme in dopamine synthesis in C. elegans, is reported to lead to age-dependent degeneration of dopaminergic neurons [46]. We repeated these experiments, and indeed found that neurodegeneration conferred by CAT-2 overexpression in dopaminergic neurons is enhanced in the gt1681 mutant background (Figure 4A). In contrast, we found CAT-2 overexpression to confer a strong resistance toward 6-OHDA-dependent neurodegeneration in both wild-type and gt1618 backgrounds (Figure 4B). We consider it likely that 6-OHDA resistance conferred by CAT-2 overexpression can be explained by reduced 6-OHDA uptake into dopaminergic neurons in the presence of excessive levels of intracellular dopamine. Our results indicate that tsp-17 protects against 6-OHDA toxicity and toxicity caused by excessive dopamine.

<i>tsp-17 (gt1681)</i> enhances the neurodegeneration phenotype of <i>cat-2</i>-overexpressing lines, and <i>cat-2</i> overexpression protects against 6-OHDA toxicity.
Fig. 4. tsp-17 (gt1681) enhances the neurodegeneration phenotype of cat-2-overexpressing lines, and cat-2 overexpression protects against 6-OHDA toxicity.
A. cat-2 induced neurodegeneration. Analysis of cat-2-overexpressing stains UA57 baIn4 [pdat-1::gfp pdat-1::cat-2] and TG2402 baIn4[pdat-1::gfp pdat-1::cat-2]; tsp-17(gt1681). Error bars represent standard deviation. Asterisks represent statistical difference between cat-2::gfp adults on days 5 and 7 (**p<0.005). B. cat-2 overexpression suppresses 6-OHDA-induced neurotoxicity. Experiments were done in triplicate and the average is shown. Data presented is from scoring the extent of neurodegeneration 72 h post 6-OHDA intoxication.

Since these genetic interactions suggest that dopamine levels could be altered in tsp-17 mutants, we next investigated behavioral phenotypes associated with dopamine. Dopamine synthesis and release are required for the basal slowing response, in which worms reduce their speed when encountering a bacterial lawn [36]. We did not observe a defect in this response, indicating that both dopamine synthesis and extracellular dopamine sensing by receptors are intact in tsp-17 mutants (Figure S5A). One of the most accessible phenotypes thought to be associated with excessive extracellular dopamine is the SWIP (Swimming Induced Paralysis) phenotype [37]. While wild-type worms placed into a drop of water maintain their thrashing frequency dat-1 mutants become progressively paralyzed. The SWIP phenotype is ascribed to excessive extracellular dopamine as a consequence of the reuptake defect in the dat-1 mutant. Excessive extracellular dopamine triggers paralysis by hyperactivating the DOP-3 receptor expressed on cholinergic neurons and hence blocking acetylcholine release [33]. To perform this experiment, we placed L4 worms into drops of water and scored their ability to swim over a period of 30 minutes. As expected, we found that wild-type but not dat-1 mutant worms can swim for 30 minutes with no change in the speed or pattern of swimming. All four tsp-17 mutants showed a partial SWIP phenotype (Figure 5A). This phenotype is probably caused by dopaminergic signaling because it can be rescued by deletion of the dop-3 dopamine receptor and by deletion of the cat-2 tyrosine hydroxylase (Figure 5A and Figure 5B). It was surprising to find a SWIP phenotype in tsp-17 mutants as we argue that tsp-17 inhibits dat-1 function (see below). While elucidating the exact mechanism of how TSP-17 affects behavioral phenotypes will require further investigation we speculate that hyper-activation of DAT-1 in tsp-17 strains could trigger a feedback loop that transiently enhance extracellular dopamine levels inducing the weak SWIP phenotype we observe.

Behavioral phenotypes associated with <i>tsp-17</i> mutants.
Fig. 5. Behavioral phenotypes associated with tsp-17 mutants.
A. Quantitative analysis of SWIP behavior at L4-stage, over 30 minutes. B. The SWIP phenotype of tsp-17(tm4995) in L4-stage worms is rescued by dop-3 deletion. C. Quantitative analysis of SWIP behavior in L1-stage worms over 20 min. D. The SWIP phenotype of tsp-17(tm4995) at L1 stage is not rescued by dop-3 deletion. Assays were done in triplicate for the total number of worms indicated by N values. Error bars represent the standard error of the mean. Asterisks represent statistically significant differences from the wild-type (***p<0.01). To facilitate comparison, strains are indicated by the same color code.

We also tested for a SWIP phenotype in L1 stage worms, and found that all tsp-17 mutants tested, except the gt1681 allele, behaved similarly to dat-1 mutants (Figure 5C, D). This phenotype, however, is not suppressed by a dop-3 mutation or blocked by a cat-2 mutation (Figure 5D and Figure S5B). We discovered that the “L1 SWIP phenotype” is linked to lethality because worms placed onto agar plates after SWIP assay show reduced viability (Figure S5C, D). Thus, the L1 “swimming-induced lethality” phenotype is unlikely to be related to dopamine levels. Given that TSP-17 is expressed in body wall muscles in L1 larvae, we speculate that swimming-induced lethality might be caused by a muscle defect.

To systematically test whether TSP-17 protects dopaminergic neurons by modulating dopamine metabolism, catabolism, reuptake or signaling, we performed a genetic epistasis analysis. As expected, tsp-17 dat-1 double mutants were completely resistant to 6-OHDA-induced neurodegeneration, consistent with the notion that TSP-17 does not bypass 6-OHDA uptake by the DAT-1 dopamine transporter (Figure 6A). We observed no alterations in 6-OHDA sensitivity in cat-2 (tyrosine hydroxylase), bas-1 (aromatic amino acid decarboxylase/AAADC) and cat-1 (VMAT ortholog required for dopamine packaging) tsp-17 double mutants, indicating that TSP-17 is unlikely to affect levels of dopamine synthesis or packaging (Figure S6).

Evidence for DAT-1 hyperactivation in <i>tsp-17</i> worms.
Fig. 6. Evidence for DAT-1 hyperactivation in tsp-17 worms.
A. dat-1::yfp transgenic worms (TG2470) do not exhibit hypersensitivity to 10 mM 6-OHDA. The extent of neurodegeneration was scored 72 h post 6-OHDA intoxication. Asterisks represent statistically significant differences compared to tsp-17 worms (****p<0.00001) B. More imipramine than in wild-type worms is needed to prevent neurodegeneration in tsp-17 mutants and in dat-1::yfp overexpression worms co-treated with 50 mM 6-OHDA. Data presented is from scoring the extent of neurodegeneration 72 h post 6-OHDA intoxication. The imipramine concentration is indicated on the x axis. N, total number of worms from each strain examined for every treatment. Error bars represent the standard error of the mean. Asterisks (below top bar) represent statistically significant differences compared to wild-type; worms treated with 0.125 mM imipramine are compared (****p<0.00001). Lower bars indicate difference within individual strains (no imipramine compared to 0.125 mM imipramine; *p<0.05, *p<0.005, ****p<0.00001) C., D. [3H]-dopamine (DA) uptake in wild-type and tsp-17 worms. Uptake assays were performed using 50 nM (C) and 250 nM [3H]-DA (D).

As 6-OHDA can enter dopaminergic neurons through the DAT-1 transporter owing to its structural similarity to dopamine [3], [47], we wondered whether DAT-1 localization or activity is modified in a tsp-17 mutant background. Having established that 6-OHDA hypersensitivity in tsp-17 worms depends on the DAT-1 transporter (Figure 6A), we tested the hypothesis that enhanced DAT-1 transporter activity may contribute to enhanced 6-OHDA-mediated neurotoxicity. Using a functional pdat-1::dat-1::YFP translational fusion, we found that overexpression of this transgene generated by bombardment does not confer overt 6-OHDA hypersensitivity (Figure 6A, Figure S7). Furthermore, the localization of DAT-1::YFP was similar between wild-type and tsp-17 mutants worms (Figure S8A), a notion further confirmed by Structural Illumination ‘super resolution’ images of CEP dendrites (Figure S8B). Additionally, photobleaching experiments indicated that ∼half of DAT-1::YFP is in the mobile fraction and that the t1/2 is around 30 seconds in both wild-type and tsp-17(gt1681) worms (Figure S8C–E). We thus aimed to test whether TSP-17 negatively regulates DAT-1 activity using a pharmacological approach. We confirmed previous reports that imipramine specifically inhibits the DAT-1 transporter in the worm [3] (Figure 6B, left panels, wild-type 0.25 mM and 1 mM). We reasoned that if DAT-1 is hyperactive in tsp-17 (gt1681), relatively more imipramine should be needed to inhibit DAT-1 activity and prevent neurodegeneration. We thus treated wild-type, tsp-17 (gt1681) worms and wild-type worms overexpressing DAT-1::YFP with 10 mM 6-OHDA and increasing doses of imipramine (Figure 6B, middle and right panels). We indeed found that higher levels of imipramine are needed to reduce neurodegeneration in DAT-1::YFP overexpressing worms and in tsp-17 (gt1681) worms, and that the effect being stronger in the tsp-17 (gt1681) mutant. Reduced levels of neurodegeneration levels were most clearly observed when concentrations of 0.125 mM and 0.25 mM imipramine were used (Figure 6B). This result provides evidence that DAT-1 activity may be higher in the tsp-17 mutant background. We aimed to provide further support for this hypothesis by directly measuring dopamine uptake, following previously described procedures. We macerated C. elegans embryos to establish primary embryonic cell cultures, and used these for dopamine uptake assays [48], [49]. Using two concentrations of tritiated dopamine, we indeed found increased dopamine uptake in tsp-17 mutants (Figure 6C, D). We note that we found this in 7/8 repeat experiments. However, we also note that only a very small proportion of tissue culture cells are dopaminergic neurons and that the absolute amount of dopamine uptake is low especially in the wild-type background.

Our combined genetic, pharmacological and biochemical analysis suggests that TSP-17 modulates DAT-1 activity. Previous studies using tissue culture-based assays demonstrated that dopamine receptor activation might promote DAT-1 activity [25], [50], [51]. Consistent with these results, we found dop-2 and dop-3 mutant worms to be partially resistant to high doses of 6-OHDA compared to wild-type (Figure 7A). We therefore investigated whether tsp-17 genetically interacts with dopamine receptors to modify DAT-1 activity and confer differential 6-OHDA sensitivity. This was done by assessing the sensitivity of tsp-17 mutants in the absence of the C. elegans DOP-1 D1-like receptor and/or in the absence of the DOP-2 and/or DOP-3 D2-like receptors. C. elegans DOP-1 is expressed in a variety of cells, including cholinergic neurons, mechanosensory neurons, head muscles and neuronal support cells. DOP-3 is expressed postsynaptically and its antagonism of DOP-1 in cholinergic neurons is required for the regulation of locomotion [33]. The DOP-2 receptor is expressed both postsynaptically and presynaptically. When expressed presynaptically, it acts as an autoreceptor on the plasma membrane of dopaminergic neurons. We found that dop-1; tsp-17 (gt1681) was as sensitive to 6-OHDA as the respective tsp-17 single mutant. In contrast, 6-OHDA hypersensitivity was reduced in dop-2; tsp-17 (gt1681) and dop-2; tsp-17 (tm4994) and in dop-3; tsp-17 (gt1681) and dop-3; tsp-17 (tm4994) double mutant worms (Figure 7B, C and Figure S9) Our genetic data thus argue that TSP-17 might inhibit DOP-2 and DOP-3 function, which in turn might be required for full DAT-1 transporter activity (Figure 7A, E). Given that deletion of dop-2 and dop-3 only partially rescues 6-OHDA hypersensitivity in tsp-17 mutants, we speculate that TSP-17 also inhibits DAT-1 activity independently of DOP-2 and DOP-3.

Dopamine receptors act antagonistically to modulate the sensitivity of <i>tsp-17 (gt1681)</i> mutants to 6-OHDA.
Fig. 7. Dopamine receptors act antagonistically to modulate the sensitivity of tsp-17 (gt1681) mutants to 6-OHDA.
Worms of the indicated genotypes were intoxicated with A. 50 mM, B. 10 mM 6-OHDA and C. 5 mM 6-OHDA and scored for neurodegeneration 72 h post intoxication. Experiments were done in triplicate and the average data is presented. N, total number of animals examined for each strain. Error bars represent the standard error of the mean. Asterisks represent statistically significant differences (***p<0.0001, ****p<0.00001). D. Evidence for a direct interaction between DOP-2 and TSP-17. Growth on -Leu, -Trp, -His (left panel) and -Leu, -Trp, -His, -Ade (middle panel) plates is shown. The right panel depicts a β-galactosidase assay. E. Working model as to how TSP-17 might interact with DAT-1 and DOP-2 to modulate level of DAT-1 activity. Arrows indicate activation. T-bars indicate repression. The question mark indicates that we do not know the mechanism of DAT-1 inhibition by TSP-17.

We next aimed to investigate how TSP-17 might regulate DAT-1 or D2-like receptors to modulate DAT-1 activity. Given that these are integral membrane proteins, we employed the split-ubiquitin membrane-based yeast two-hybrid system [52]. In this system, a C-terminal ubiquitin moiety fused to a transmembrane protein and a transcription factor is used a bait. An N-terminal ubiquitin moiety is used as the “prey.” Upon “reconstruction” of the split ubiquitin, this molecule is recognized by a protease, which cleaves the transcription factor, thus promoting reporter gene activation. By employing various bait and prey fusions with TSP-17, DAT-1 and DOP-2, we could not find a direct interaction between TSP-17 and DAT-1 using the split-ubiquitin system (Figure 7D). In contrast, we found that DOP-2 and TSP-17 may indeed interact. The specificity of this interaction was clearly revealed when the beta-galactosidase reporter assay was used as an output. In addition, yeast colony formation on his-3 or his-3 ade-2 plates was enhanced when the corresponding reporters where used (Figure 7D). Thus, TSP-17 might modulate DOP-2 activity by a direct physical interaction, consistent with TSP-17 affecting ligand binding, downstream signaling or membrane trafficking of DOP-2-like receptors. Our genetic data also suggest that TSP-17 might also act via other factors to dampen DAT-1 activity (Figure 7B).


Using C. elegans as a model and employing unbiased genetic approaches, we aimed to find neuroprotective genes that alleviate the 6-OHDA-induced degeneration of dopaminergic neurons. Based on our genetic data, which is supported by the characterization of several alleles and transgenic rescue experiments, we provide compelling evidence that TSP-17 protects dopaminergic neurons from 6-OHDA-mediated toxicity. TSP-17 appears to function in dopaminergic neurons, and our combined genetic, pharmacological and biochemical evidence suggests that it might act by antagonizing DAT-1 dopamine transporter activity. We do not know how TSP-17 regulates DAT-1 at a mechanistic level.

TSP-17 is a member of the evolutionarily conserved family of tetraspanins, comprising 20–50 kDa membrane proteins that contain four transmembrane domains. A characteristic feature of tetraspanins is their ability to form lateral associations with each other and with other proteins. Such interactions are thought to lead to a dynamic assembly, resulting in the formation of a network of molecular interactions referred to as the tetraspanin web [41], [53]. Tetraspanins are thought to have regulatory functions in the ligand binding, downstream signaling, protein trafficking and proteolytic activities of associated proteins [42], [54]. In C. elegans, only two tetraspanins have known functions. TSP-15 appears to be required to activate the BLI-3 dual oxidase to regulate H202 production at the plasma membrane and thus alter dityrosine cross-linkage of extracellular matrix proteins [44], [55]. Genetic evidence suggests that TSP-12, most closely related to human TSPAN33, appears to facilitate Notch signaling redundantly with TSP-14. Thus conserved tetraspanins likely function by facilitating γ-secretase cleavage of the membrane-bound form of Notch, thus promoting nuclear localization of this transcription factor [43].

DAT-1 hyperactivity in the tsp-17 mutants could result from altered DAT-1 localization or abundance at the cell membrane; alternatively, TSP-17 might indirectly regulate DAT-1 activity. Using a functional DAT-1::YFP construct, we did not see any obvious change in DAT-1 expression, localization, or change in half life in tsp-17 mutants and we thus favor the idea that TSP-17 regulates DAT-1 activity. Our finding that TSP-17 genetically and biochemically interacts with the DOP-2 D2-like dopamine receptor, suggests an indirect mode of DAT-1 regulation by TSP-17 (Figure 7E). Our genetic analysis provides evidence that TSP-17 might in part regulate DAT-1 via DOP-2 and DOP-3 dopamine receptors (Figure 7E). We found that depletion of the D2-like dopamine receptors, DOP-2 and/or DOP-3, in tsp-17 mutants leads to a moderate reduction in the 6-OHDA hypersensitivity conferred by tsp-17, while D2-like dopamine receptor single knockout strains show the same 6-OHDA sensitivity as wild-type worms. Thus, our analysis suggests that tsp-17 genetically interacts with D2-like dopamine receptors, in line with our observation that TSP-17 directly binds to DOP-2. In mammalian systems, dopamine autoreceptors are reported to have a major role in providing inhibitory feedback to adjust the rate of neuronal firing, dopamine synthesis and dopamine release in response to the dopamine level in the synaptic cleft [30], [32]. Several studies suggest that vertebrate D2 dopamine receptors also modulate DAT-1 activity to regulate the dopamine level in the synaptic cleft. Cass and Gerhardt used pharmacological approaches to demonstrate that inhibition of D2 class dopamine receptors significantly inhibits DAT function [50]. Two independent studies provided evidence that D2 receptors regulate both the activity and cell surface expression of DAT-1 [25], [51]. Nevertheless, further investigations are required to establish functional links between C. elegans DOP-2 receptors and DAT-1 activity. The ability of TSP-17 to inhibit DAT-1 both via DOP-2 and independent of D2-like receptors (Figure 7E) suggests that TSP-17 modulates the activity of multiple signaling proteins. Indeed, our observation of excessive neurodegeneration following wild-type, and especially mutant, TSP-17 overexpression in dopaminergic neurons hints that malfunctioning and/or excessive TSP-17 blocks pathways needed to maintain the integrity of dopaminergic neurons. The enhanced defect associated with overexpression of mutant TSP-17 that fails to show the correct cytoplasmic localization hints the neurotoxicity might be conferred by the sequestration of TSP-17 interacting proteins essential for neuronal survival.

Dopamine neuronal dysfunction has been associated with several common neurobehavioral disorders, including drug addiction, schizophrenia and attention-deficit hyperactivity disorder [32], [56][58]. The DAT-1 dopamine transporter plays a central role in dopamine signaling, and it is likely to be subjected to complex modes of regulation. DAT-1 is the target of psychoactive addictive drugs such as cocaine and amphetamine, and DAT1 overexpression leads to increased amphetamine sensitivity [59][63]. Mechanisms related to dopamine signaling tend to be evolutionarily conserved. Thus, studies aimed to genetically define modulators of dopamine signaling and 6-OHDA-mediated toxicity will provide important insights into the mechanisms of dopamine signaling in health and disease.

Idiopathic PD is thought to be triggered by a combination of environmental factors and genetic susceptibility, and a case has been made that exposure to environmental toxins such as the pesticides paraquat and rotenone leads to increased PD [9]. Indeed, chemical and tissue culture studies have provided evidence that increased dopamine levels may lead to enhanced neurodegeneration, probably through the generation of toxic intermediates such as the neurotoxic product of dopamine oxidation, 6-OHDA [13], [15], [64][68]. The specificity of 6-OHDA entry into dopamine neurons depends on DAT, and DAT antagonists can block uptake [3], [4], [11], [47]. Interestingly, DAT-1 hyperactivity in tsp-17 mutants further enhances the neurodegeneration conferred by elevated dopamine synthesis in CAT2 tyrosine hydroxylase-overexpressing worm strains. Thus, DAT-1 hyperactivity might enhance neurodegeneration by further increasing the intracellular concentration of dopamine and/or toxic metabolites. DAT1 expression or activity has not been linked to PD, but it is intriguing that among dopamine neurons those residing in the substantia nigra express the highest DAT levels in vivo and are most strongly affected in PD [4], [60].

Materials and Methods

C. elegans strains and maintenance

Strains were grown at 20°C under standard conditions, unless indicated otherwise. N2 Bristol was used as the wild-type strain. The tsp-17(tm4994) and tsp-17(tm5169) mutants were generated and kindly provided by Shohei Mitani of the National Bioresource Project for the Nematode (http://www.shigen.nig.ac.jp/c.elegans/). Details of the respective alleles are described by the National Bioresource Project for the Nematode and by WormBase (www.wormbase.org). All mutants were outcrossed a minimum of four times to the TG2435 vtIs1[pdat-1::gfp] strain originally generated by the Blakely laboratory (BY200) and repeatedly crossed into the N2 background.


TG2435 vtIs1[pdat-1::gfp; rol-6] V,

TG1681 vtIs1 V; tsp-17(gt1681) X,

TG2436 vtIs1 V; tsp-17(tm4994) X,

TG2437 vtIs1 V; tsp-17(tm5169) X,

TG2438 vtIs1 V; tsp-17(gk276386) X,

TG2462 vtIs1 V; CB4856,

TG2463 vtIs1 V; lon-2(e678) unc-20(e112) X,

TG2464 vtIs1 V; tsp-17(gt1681) unc-20(e112) X,

TG2465 vtIs1 V; tsp-17(gt1681) lon-2(e678) X,

TG2395 cat-2(e1112) II; vtIs1 V,

TG2394 cat-2(e1112) II; vtIs1 V; tsp-17(gt1681) X,

TG2396 bas-1(tm351) III; vtIs1 V,

TG2397 bas-1(tm351) III; vtIs1 V; tsp-17(gt1681) X,

TG2399 vtIs1 V; cat-1(e1111) X,

TG2398 vtIs1 V; cat-1(e1111) tsp-17(gt1681) X,

TG2400 dat-1(ok157) III; vtIs1 V,

TG2401 dat-1(ok157) III; vtIs1 V; tsp-17(gt1681) X,

TG2404 amx-1(ok659) III; vtIs1 V,

TG2403 amx-1(ok659) III; vtIs1 V; tsp-17(gt1681) X,

TG2406 amx-2(ok1235) I; vtIs1 V,

TG2405 amx-2(ok1235) I; vtIs1 V; tsp-17(gt1681) X,

TG2408 amx-2(ok1235) I; amx-1(ok659) III; vtIs1 V,

TG2407amx-2(ok1235) I; amx-1(ok659) III; vtIs1 V; tsp-17(gt1681) X,

TG2410 vtIs1 V; dop-1(vs100) X,

TG2409 vtIs1 V; dop-1(vs100) tsp-17(gt1681) X,

TG2412 vtIs1 dop-2(vs105) V,

TG2411 vtIs1 dop-2(vs105) V; tsp-17(gt1681) X,

TG2414 vtIs1 V; dop-3(vs106) X,

TG2413 vtIs1 V; dop-3(vs106) tsp-17(gt1681) X,

TG2466 vtIs1 dop-2(vs105) V; dop-3(vs106) X,

TG2467 vtIs1 dop-2(vs105) V; dop-3(vs106) tsp-17(gt1681) X,

TG2415 vtIs1 dop-2(vs105) V; dop-1(vs100) dop-3(vs106) X,

TG2416 vtIs1 dop-2(vs105) V; dop-1(vs100) dop-3(vs106) tsp-17(gt1681) X,

UA57 baIn4[pdat-1::gfp pdat-1::cat-2],

TG2402 baIn4[pdat-1::gfp pdat-1::cat-2],; tsp-17 (gt1681) X,

TG2470 gtIn2469[pdat-1::dat-1::yfp::let-858 3′UTR, unc-119(+)]; gtIn2468[pdat-1::mcherry::let858 3′UTR, unc-119(+)]; unc-119(ed3) III,

TG2471 gtIn2469[pdat-1::dat-1::yfp::let-858 3′UTR, unc-119(+)]; gtIn2468[pdat-1::mcherry::let858 3′UTR, unc-119(+)]; unc-119(ed3) III; tsp-17(gt1681) X,

TG2439 gtIn2439[ptsp-17::tsp-17::gfp::tsp-17 3′UTR, pdat-1::mcherry::let858 3′UTR, unc-119(+)]; unc-119(ed3) III,

TG2472 tsp-17(gt1681) X; gtIn2439[ptsp-17::tsp-17::gfp::tsp-17 3′UTR, pdat-1::mcherry::let858 3′UTR, unc-119(+)]; unc-119(ed3) III,

TG2440 gtEx2440[pdat-1::tsp-17::cfp:: let-858 3′UTR, unc-119(+)]; unc-119(ed3) III; vtIs1 [pdat-1::gfp; rol-6] V,

TG2473 vtIs1 [pdat-1::gfp; rol-6] V; tsp-17(gt1681) X; gtEx2440 [pdat-1::tsp-17::cfp:: let-858 3′ UTR, unc-119(+)],

TG2474 vtIs1 [pdat-1::gfp; rol-6] V; unc-119(ed3) III; gtEx2474[pdat-1::tsp-17(G74E)::cfp:: let-858 3′UTR, unc-119(+)],

TG2478 cat-2(e1112) II; vtIs1V; tsp-17(tm4994) X,

TG2475 dat-1(ok157) III; vtIs1V; tsp-17(tm4995) X,

TG2477 vtIs1; dop-3(vs106) tsp-17(tm4995) X,

TG2476 dat-1(ok157) III; vtIs1V; dop-3(vs106) X,

Generation of transgenic worms and constructs

NM001, NM002, Pb1001, PbI002, PbI003 and AH001 plasmid sequences can be obtained upon request.

Plasmids generated in this study are as follows:

NM001 pRH21-ptsp-17::tsp-17::gfp::tsp-17 3′UTR

NM002 pRH21-ptsp-17::tsp-17(gt1681)::gfp::tsp-17 3′UTR

PbI001 pRH21-pdat-1::mcherry::let858 3′UTR

PbI002 pRH21-pdat-1::tsp-17::cfp::tsp-17 3′UTR

PbI003 pRH21-dat-1::tsp-17(gt1681)::cfp::tsp-17 3′UTR

AH001 pRH21-pdat-1::dat-1::yfp::let-858 3′UTR

NM003 pBT3-STE-dop-2c-Cub

NM004 pBT3-STE-dat-1-Cub

NM005 pPR3-STE-tsp-171b-NubG

Plasmids were generated using the following primers:

dat-1_pmt_AscI_F, atatGGCGCGCCaatgtttctagtcgtttttgta

dat-1_pmt_SgfI_R, ctccGCGATCGCggctaaaaattgttgagattcg

mCherry_NotI_F, ggagGCGGCCGCatggtctcaaagggtgaagaag

mCherry_FseI_R, cctaGGCCGGCCccttatacaattcatccatgccacc

F_pmt-tsp-17_AscI, agtcGGCGCGCCagtctgaaaaacaacagagttagatg

F_ATG_SgfI_tsp-17a_Cter, ggagGCGATCGCatgcttctcgacccgaaac

R_tsp-17gnc_NO-TAA_cNotI, atgcGCGGCCGCcgtagtcatctcgaattacatgg

F_PacI_TAA-3utr_tsp17, gtacTTAATTAAtaaatcactctacggtgaatta

R_ApaI_3utr_tsp-17, cagtGGGCCCtcactaatatatgttctcagtcc

GFP-CFP_NotI_F, GCGGCCGCatgagtaaaggagaagaacttttc

GFP_FseI_R, GGCCGGCCccttgtatggccggctagcg

F_dop-2c_pBT3STE, gctaGGCCATTACGGCCgaggccggagagacatggaat

R_dop2c_pBT3STE, gctaGGCCGAGGCGGCCccgacatgcgcctgcttgttact



F_tsp-17_pPR3STE, gctaGGCCATTACGGCCTTgcaacagaacgtgatggc

R_tsp-17_pPR3STE, gtcaGGCCGAGGCGGCCCCgtagtcatctcgaattacatggta

The TG2470 and TG2439 strains were generated by biolistic bombardment of unc-119(ed3) worms with AH001 and NM001 plasmids, respectively. The TG2440 and TG2474 strains were generated by microinjections of unc-119 (ed3) mutants.

Mutagenesis and mapping

EMS was added to 4 ml synchronized young adult worms in M9 buffer to a final concentration of 25 mM and incubated for 4 h at 20°C. Mutagenized worms were washed in M9 buffer and incubated at 15°C. Synchronous F1-generation L1 larvae were used for screening. F2-generation L1 larvae from mutagenized TG2435 dat-1::gfp (BY200) worms were used for the mutagenesis screen. L1 larvae were intoxicated with 10 mM 6-OHDA. After 72 h, worms with the highest incidence of neurodegeneration were isolated and scored as hypersensitive. SNP mapping of mutants was done as previously described [69].

Drug treatment of worms

To obtain synchronized L1 larvae, 1–10 adult worms (24 h post-L4 stage) were incubated in 70 µl M9 without food on at 20°C, with shaking at 500 rpm for 27–40 h to lay eggs. After hatching, all L1 larvae were collected. Approximately 50 L1 larvae were added to an assay mix (50 µl) containing 10 mM 6-OHDA and 40 mM ascorbic acid, and incubated for 1 h at 20°C, with shaking at 500 rpm. For co-treatment with imipramine or haloperidol, the respective compounds were added to the assay mix at the same time as 6-OHDA. After a 1-h incubation, M9 buffer (100 µl) was added to the assay mix, and the solution containing L1 worms was then transferred to an unseeded NGM plate. After 30 min, L1 worms were individually picked and transferred onto a fresh NGM plate seeded with a line of OP50 bacteria to ease subsequent scoring. Intoxicated worms were incubated at 20°C and scored for dopaminergic neurodegeneration every 24 h for 3 days. All 6-OHDA treatments were done in triplicate and at least 80–100 worms were tested for each strain and condition.

Swimming-induced paralysis assay

All worms used for SWIP analysis were grown on NGM plates seeded with E. coli OP50 bacteria. For each test, 5–10 L4 hermaphrodites or 10 L1 worms were placed into 40 µl water in a single well of a Pyrex Spot Plate. Paralyzed worms were counted at 1-min intervals using a Leica dissecting microscope [70]. L1 worms were hand picked from seeded plates, 12 hours after the addition of embryos, obtained by bleaching.

Scoring neuronal degeneration and image acquisition

For semi-quantitative analyses of 6-OHDA-induced degeneration, worms were examined using a Leica fluorescent dissecting microscope. The absence of all eight dopaminergic neurons in worms was scored as “complete loss.” The presence of a complete, intact set of eight dopaminergic neurons was scored as “no loss.” Any intermediate situation, for example a damaged or absent subset of dopaminergic neurons or missing dendrite portions, was scored as a “partial loss.” Neurodegeneration resulting from cat-2 overexpression was scored using developmentally synchronized worms, as indicated. A DeltaVision microscope (Applied Precision) was used to acquire images. All images were analyzed using softWoRx Suite and softWoRx Explorer software (Applied Precision).

DNA constructs for the split-ubiquitin system

Total RNA was isolated and reverse transcribed from wild-type C. elegans (N2) using an RNeasy mini kit (QIAGEN). Coding regions of dop-2c (K09G1.4c) and dat-1 (T23G5.5) were amplified and cloned into pBT3-STE vectors (Dual Systems Schlieren) for expression of a fusion protein containing the C-terminal half of ubiquitin (Cub) and the artificial transcription factor LexA-VP16. tsp-17b (C02F12.1b) cDNA was amplified and cloned into prey vector pPR3-STE for expression of a fusion protein containing a mutated version of the N-terminal half of ubiquitin (NubG). Constructs were verified by DNA sequencing, and sequences of the respective constructs can be provided upon request. Yeast transformations and pairwise interaction assays were done according to the protocol of Dualsystems Schlieren.

C. elegans cell culture and DAT-1 uptake assay

Embryonic cells were prepared as described previously (Christensen, M, et al 2002, Neuron). The uptake assay was done according to Carvelli et al. (2004). Briefly, C. elegans cells cultured for 2 days were washed twice with KRH buffer (120 mM NaCl, 4.7 mM KCl, 1.2 mM KH2P04, 10 mM Hepes, 2.2 CaC12, 10 mM glucose, 0.1 mM ascorbic acid and 0.1 mM tropolone and 0.1 mM pargyline mono amine oxidase inhibitors) and incubated with 50 or 250 nM [3H]-dopamine for 20 min at room temperature. Uptake was terminated by three washes of ice-cold KRH buffer, and cells were lysed by incubation with 1% SDS for 20 min. [3H]-dopamine uptake was measured in each genetic background, based on radioactive counts, using a scintillation counter (PerkinElmer Liquid Scintillation Analyzer Tri-Carb 1800TR). Total cell numbers were determined with a hemocytometer and were used to normalize radioactive counts. Cell numbers varied between experiments but were not biased towards mutant or control strain: There were 400,000/400,000, 75,000/150,000 and 1,000,000/400,000 cells for control/mutant strain, respectively. Cell extraction and uptake assays were always done simultaneously for both strains. The error bars depict the standard error of the means (SEM).

Statistical analysis

Neurodegeneration and SWIP assay data are presented as the average of three biological replicates, and error bars represent the standard error of the mean, unless otherwise indicated. When assaying neurodegeneration statistical significance was calculated using the Chi-Sqare test using Yates p-values. http://www.quantpsy.org/chisq/chisq.htm. The statistical significance of differences in the SWIP assays (Figure 5) was calculated using the two-tailed t-test.

Supporting Information

Attachment 1

Attachment 2

Attachment 3

Attachment 4

Attachment 5

Attachment 6

Attachment 7

Attachment 8

Attachment 9


1. CalneDB, LangstonJW (1983) Aetiology of Parkinson's disease. Lancet 2: 1457–1459.

2. ZigmondMJ, BurkeRE (2002) pathophysiology of parkinson's disease. Fifth generation of progess American college of Neuropsychopharmacology Williams and Wilkens 1781–1794.

3. NassR, HallDH, MillerDM3rd, BlakelyRD (2002) Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America 99: 3264–3269.

4. NassR, BlakelyRD (2003) The Caenorhabditis elegans dopaminergic system: opportunities for insights into dopamine transport and neurodegeneration. Annual review of pharmacology and toxicology 43: 521–544.

5. ChaseTN (1997) A gene for Parkinson disease. Archives of neurology 54: 1156–1157.

6. LaiCH, ChouCY, Ch'angLY, LiuCS, LinW (2000) Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics. Genome research 10: 703–713.

7. KleinC, WestenbergerA (2012) Genetics of Parkinson's disease. Cold Spring Harbor perspectives in medicine 2: a008888.

8. LangstonJW, BallardP, TetrudJW, IrwinI (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980.

9. PriyadarshiA, KhuderSA, SchaubEA, PriyadarshiSS (2001) Environmental risk factors and Parkinson's disease: a metaanalysis. Environmental research 86: 122–127.

10. TiptonKF, SingerTP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Journal of neurochemistry 61: 1191–1206.

11. GlinkaY, GassenM, YoudimMB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. Journal of neural transmission Supplementum 50: 55–66.

12. KostrzewaRM, JacobowitzDM (1974) Pharmacological actions of 6-hydroxydopamine. Pharmacological reviews 26: 199–288.

13. AndrewR, WatsonDG, BestSA, MidgleyJM, WenlongH, et al. (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochemical research 18: 1175–1177.

14. TieuK (2011) A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harbor perspectives in medicine 1: a009316.

15. FahnS, CohenG (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Annals of neurology 32: 804–812.

16. BoveJ, PerierC (2012) Neurotoxin-based models of Parkinson's disease. Neuroscience 211: 51–76.

17. BirkmayerW, HornykiewiczO (1998) The effect of l-3,4-dihydroxyphenylalanine ( = DOPA) on akinesia in parkinsonism. Parkinsonism & related disorders 4: 59–60.

18. CotziasGC, PapavasiliouPS, GelleneR (1969) Modification of Parkinsonism–chronic treatment with L-dopa. The New England journal of medicine 280: 337–345.

19. FahnS (1999) Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Archives of neurology 56: 529–535.

20. WhiteJG, SouthgateE, ThomsonJN, BrennerS (1986) The structure of the nervous system of the nematode Caenorhabditis elegans. Philosophical transactions of the Royal Society of London Series B, Biological sciences 314: 1–340.

21. BrennerS (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71–94.

22. SulstonJ, DewM, BrennerS (1975) Dopaminergic neurons in the nematode Caenorhabditis elegans. The Journal of comparative neurology 163: 215–226.

23. TothML, SimonP, KovacsAL, VellaiT (2007) Influence of autophagy genes on ion-channel-dependent neuronal degeneration in Caenorhabditis elegans. Journal of cell science 120: 1134–1141.

24. ChenN, ReithME (2004) Interaction between dopamine and its transporter: role of intracellular sodium ions and membrane potential. Journal of neurochemistry 89: 750–765.

25. LeeFJ, PeiL, MoszczynskaA, VukusicB, FletcherPJ, et al. (2007) Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. The EMBO journal 26: 2127–2136.

26. MoszczynskaA, SalehJ, ZhangH, VukusicB, LeeFJ, et al. (2007) Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. Journal of molecular neuroscience: MN 32: 217–227.

27. LeeFJ, LiuF, PristupaZB, NiznikHB (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 15: 916–926.

28. ChangMY, LeeSH, KimJH, LeeKH, KimYS, et al. (2001) Protein kinase C-mediated functional regulation of dopamine transporter is not achieved by direct phosphorylation of the dopamine transporter protein. Journal of neurochemistry 77: 754–761.

29. ValloneD, PicettiR, BorrelliE (2000) Structure and function of dopamine receptors. Neuroscience and biobehavioral reviews 24: 125–132.

30. MissaleC, NashSR, RobinsonSW, JaberM, CaronMG (1998) Dopamine receptors: from structure to function. Physiological reviews 78: 189–225.

31. SokoloffP, GirosB, MartresMP, BouthenetML, SchwartzJC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151.

32. BeaulieuJM, GainetdinovRR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacological reviews 63: 182–217.

33. AllenAT, MaherKN, WaniKA, BettsKE, ChaseDL (2011) Coexpressed D1- and D2-like dopamine receptors antagonistically modulate acetylcholine release in Caenorhabditis elegans. Genetics 188: 579–590.

34. ZhouQY, PalmiterRD (1995) Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83: 1197–1209.

35. SzczypkaMS, RaineyMA, PalmiterRD (2000) Dopamine is required for hyperphagia in Lep(ob/ob) mice. Nature genetics 25: 102–104.

36. SawinER, RanganathanR, HorvitzHR (2000) C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26: 619–631.

37. McDonaldPW, HardieSL, JessenTN, CarvelliL, MatthiesDS, et al. (2007) Vigorous motor activity in Caenorhabditis elegans requires efficient clearance of dopamine mediated by synaptic localization of the dopamine transporter DAT-1. The Journal of neuroscience: the official journal of the Society for Neuroscience 27: 14216–14227.

38. ThompsonO, EdgleyM, StrasbourgerP, FlibotteS, EwingB, et al. (2013) The million mutation project: a new approach to genetics in Caenorhabditis elegans. Genome research 23: 1749–1762.

39. BoucheixC, BenoitP, FrachetP, BillardM, WorthingtonRE, et al. (1991) Molecular cloning of the CD9 antigen. A new family of cell surface proteins. The Journal of biological chemistry 266: 117–122.

40. BoucheixC, DucGH, JasminC, RubinsteinE (2001) Tetraspanins and malignancy. Expert reviews in molecular medicine 2001: 1–17.

41. BoucheixC, RubinsteinE (2001) Tetraspanins. Cellular and molecular life sciences: CMLS 58: 1189–1205.

42. RubinsteinE (2011) The complexity of tetraspanins. Biochemical Society transactions 39: 501–505.

43. DunnCD, SulisML, FerrandoAA, GreenwaldI (2010) A conserved tetraspanin subfamily promotes Notch signaling in Caenorhabditis elegans and in human cells. Proceedings of the National Academy of Sciences of the United States of America 107: 5907–5912.

44. MoribeH, YochemJ, YamadaH, TabuseY, FujimotoT, et al. (2004) Tetraspanin protein (TSP-15) is required for epidermal integrity in Caenorhabditis elegans. Journal of cell science 117: 5209–5220.

45. Garcia-EspanaA, ChungPJ, SarkarIN, StinerE, SunTT, et al. (2008) Appearance of new tetraspanin genes during vertebrate evolution. Genomics 91: 326–334.

46. CaoS, GelwixCC, CaldwellKA, CaldwellGA (2005) Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. The Journal of neuroscience: the official journal of the Society for Neuroscience 25: 3801–3812.

47. JayanthiLD, ApparsundaramS, MaloneMD, WardE, MillerDM, et al. (1998) The Caenorhabditis elegans gene T23G5.5 encodes an antidepressant- and cocaine-sensitive dopamine transporter. Molecular pharmacology 54: 601–609.

48. StrangeK, ChristensenM, MorrisonR (2007) Primary culture of Caenorhabditis elegans developing embryo cells for electrophysiological, cell biological and molecular studies. Nat Protoc 2: 1003–1012.

49. CarvelliL, McDonaldPW, BlakelyRD, DefeliceLJ (2004) Dopamine transporters depolarize neurons by a channel mechanism. Proceedings of the National Academy of Sciences of the United States of America 101: 16046–16051.

50. CassWA, GerhardtGA (1994) Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neuroscience letters 176: 259–263.

51. BolanEA, KivellB, JaligamV, OzM, JayanthiLD, et al. (2007) D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Molecular pharmacology 71: 1222–1232.

52. ThaminyS, MillerJ, StagljarI (2004) The split-ubiquitin membrane-based yeast two-hybrid system. Methods Mol Biol 261: 297–312.

53. RubinsteinE, Le NaourF, Lagaudriere-GesbertC, BillardM, ConjeaudH, et al. (1996) CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. European journal of immunology 26: 2657–2665.

54. CharrinS, le NaourF, SilvieO, MilhietPE, BoucheixC, et al. (2009) Lateral organization of membrane proteins: tetraspanins spin their web. The Biochemical journal 420: 133–154.

55. MoribeH, KonakawaR, KogaD, UshikiT, NakamuraK, et al. (2012) Tetraspanin is required for generation of reactive oxygen species by the dual oxidase system in Caenorhabditis elegans. PLoS genetics 8: e1002957.

56. SeemanP (2010) Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4: 56–73.

57. SeemanP (2011) All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 17: 118–132.

58. RangHP, DaleMM, RitterJM, FlowerRJ (2007) Antipsychotics drugs. Rang and Dale's Pharmacology 545–556.

59. GirosB, JaberM, JonesSR, WightmanRM, CaronMG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606–612.

60. UhlGR (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Annals of neurology 43: 555–560.

61. GainetdinovRR, JonesSR, FumagalliF, WightmanRM, CaronMG (1998) Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev 26: 148–153.

62. FerrisMJ, CalipariES, YorgasonJT, JonesSR (2013) Examining the complex regulation and drug-induced plasticity of dopamine release and uptake using voltammetry in brain slices. ACS Chem Neurosci 4: 693–703.

63. CalipariES, FerrisMJ, SalahpourA, CaronMG, JonesSR (2013) Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun 4: 2720.

64. JellingerK, LinertL, KienzlE, HerlingerE, YoudimMB (1995) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. Journal of neural transmission Supplementum 46: 297–314.

65. LaVoieMJ, HastingsTG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. The Journal of neuroscience: the official journal of the Society for Neuroscience 19: 1484–1491.

66. SantiagoM, MatarredonaER, GraneroL, CanoJ, MachadoA (2000) Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals. Brain research 858: 26–32.

67. MaharajH, Sukhdev MaharajD, ScheepersM, MokokongR, DayaS (2005) l-DOPA administration enhances 6-hydroxydopamine generation. Brain research 1063: 180–186.

68. GalvinJE (2006) Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 112: 115–126.

69. DavisMW, HammarlundM, HarrachT, HullettP, OlsenS, et al. (2005) Rapid single nucleotide polymorphism mapping in C. elegans. BMC Genomics 6: 118.

70. ChaseDL, PepperJS, KoelleMR (2004) Mechanism of extrasynaptic dopamine signaling in Caenorhabditis elegans. Nature neuroscience 7: 1096–1103.

Genetika Reprodukční medicína

Článek vyšel v časopise

PLOS Genetics

2014 Číslo 12

Nejčtenější v tomto čísle
Kurzy Podcasty Doporučená témata Časopisy
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.


Nemáte účet?  Registrujte se